The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
Open accessAbstract
Epidemiologic studies demonstrate that long-term use of NSAIDs is associated with a reduced risk for the development of Alzheimer disease (AD). In this study, 20 commonly used NSAIDs, dapsone, and enantiomers of flurbiprofen were analyzed for their ability to lower the level of the 42-amino-acid form of amyloid beta protein (Abeta42) in a human H4 cell line. Thirteen of the NSAIDs and the enantiomers of flurbiprofen were then tested in acute dosing studies in amyloid beta protein precursor (APP) transgenic mice, and plasma and brain levels of Abeta and the drug were evaluated. These studies show that (a). eight FDA-approved NSAIDs lower Abeta42 in vivo, (b). the ability of an NSAID to lower Abeta42 levels in cell culture is highly predicative of its in vivo activity, (c). in vivo Abeta42 lowering in mice occurs at drug levels achievable in humans, and (d). there is a significant correlation between Abeta42 lowering and levels of ibuprofen. Importantly, flurbiprofen and its enantiomers selectively lower Abeta42 levels in broken cell gamma-secretase assays, indicating that these compounds directly target the gamma-secretase complex that generates Abeta from APP. Of the compounds tested, meclofenamic acid, racemic flurbiprofen, and the purified R and S enantiomers of flurbiprofen lowered Abeta42 levels to the greatest extent. Because R-flurbiprofen reduces Abeta42 levels by targeting gamma-secretase and has reduced side effects related to inhibition of cyclooxygenase (COX), it is an excellent candidate for clinical testing as an Abeta42 lowering agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The first GSMs were discovered by recognizing that ibuprofen, indomethacin and sulindac reduce Abeta42 levels (Weggen et al., 2001) through modulation of gamma-secretase activity (Eriksen et al., 2003).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Eriksen et al., 2003
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate neurotoxicity and diseases of the nervous system
Choi, D. W. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 8,188
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., & Selkoe, D. J. (1999) · Nature · doi:10.1038/19077 · Cited by 1,959
Statins and the risk of dementia
Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,764
Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1
Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.-M., Pérez‐Tur, J., Hutton, M., Buée, L., Harigaya, Y., Yager, D., et al. (1996) · Nature · doi:10.1038/383710a0 · Cited by 1,486
Flagged first, then by citations
Research works printed but not linked: 3
- Wechter, 2000, Cancer Res., 60, 2203
- Edbauer, 2003, Nat. Cell Biol., 7, 7
- Murray, 2000, Clin. Pharmacol. Ther., 67, 103
Cited by
Sorted by citations
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253
Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965
Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines
Rubio-Perez, J. M., & Morillas-Ruiz, J. M. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/756357 · Cited by 864
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 765
The role of inflammation in Alzheimer’s disease
Tuppo, E. E., & Arias, H. R. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.07.009 · Cited by 734
Structure−Brain Exposure Relationships
Hitchcock, S. A., & Pennington, L. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060642i · Cited by 716
A century-old debate on protein aggregation and neurodegeneration enters the clinic
Lansbury, P. T., & Lashuel, H. A. (2006) · Nature · doi:10.1038/nature05290 · Cited by 691
Graham, R. K., Deng, Y., Slow, E., Haigh, B., Bissada, N., Lu, G., Pearson, J., Shehadeh, J., Bertram, L. N., Murphy, Z., et al. (2006) · Cell · doi:10.1016/j.cell.2006.04.026 · Cited by 652
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630
Alzheimer's Disease: From Pathology to Therapeutic Approaches
Jakob‐Roetne, R., & Jacobsen, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802808 · Cited by 626
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
Warner, T. D., & Mitchell, J. A. (2004) · The FASEB Journal · doi:10.1096/fj.03-0645rev · Cited by 617
Rho kinase, a promising drug target for neurological disorders
Mueller, B. K., Mack, H., & Teusch, N. E. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1719 · Cited by 609
Inflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., & Landreth, G. E. (2005) · Brain · doi:10.1093/brain/awh452 · Cited by 565
100 Years and Counting: Prospects for Defeating Alzheimer's Disease
Roberson, E. D., & Mucke, L. (2006) · Science · doi:10.1126/science.1132813 · Cited by 556
Protective effects of NSAIDs on the development of Alzheimer disease
Vlad, S. C., Miller, D. R., Kowall, N. W., & Felson, D. T. (2008) · Neurology · doi:10.1212/01.wnl.0000311269.57716.63 · Cited by 535
COX-2 and beyond: approaches to prostaglandin inhibition in human disease
FitzGerald, G. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1225 · Cited by 518
Takami, M., Nagashima, Y., Sano, Y., Ishihara, S., Morishima-Kawashima, M., Funamoto, S., & Ihara, Y. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2362-09.2009 · Cited by 498
Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy
Fakhoury, M. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170720095240 · Cited by 502
Presenilins and -Secretase: Structure, Function, and Role in Alzheimer DiseasePreprint
Strooper, B. D., Iwatsubo, T., & Wolfe, M. S. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006304 · Cited by 490
Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process
De Strooper, B. (2010) · Physiological Reviews · doi:10.1152/physrev.00023.2009 · Cited by 455
Neuroinflammatory processes in Alzheimer’s disease
Heneka, M. T., O’Banion, M. K., Terwel, D., & Kummer, M. P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0438-z · Cited by 433
Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms
Sastre, M., Klockgether, T., & Heneka, M. T. (2006) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2005.11.014 · Cited by 426
NEURODEGENERATIVE DISEASES: New Concepts of Pathogenesis and Their Therapeutic Implications
Skovronsky, D., Lee, V. M. ‐., & Trojanowski, J. Q. (2006) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100113 · Cited by 433
The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease
Minter, M. R., Taylor, J. M., & Crack, P. J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13411 · Cited by 451
Blasko, I., Stampfer‐Kountchev, M., Robatscher, P., Veerhuis, R., Eikelenboom, P., & Grubeck‐Loebenstein, B. (2004) · Aging Cell · doi:10.1111/j.1474-9728.2004.00101.x · Cited by 374
Sastre, M., Dewachter, I., Rossner, S., Bogdanovic, N., Rosen, E., Borghgraef, P., Evert, B. O., Dumitrescu-Ozimek, L., Thal, D. R., Landreth, G., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503839103 · Cited by 373
Aβ40 Inhibits Amyloid Deposition In Vivo
Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., Dickson, D. W., Golde, T., & McGowan, E. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4849-06.2007 · Cited by 359
“Our data support the strategy that selectively targeting A 42 by allosterically modulating -secretase may be preferential to nonselective inhibition of -secretase activity (Weggen et al., 2001; Eriksen et al., 2003; Lleo et al., 2004).”
MethodAlzheimer's Disease and Mild Cognitive Impairment
Kelley, B. J., & Petersen, R. C. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.008 · Cited by 335
Inflammation and Alzheimer’s disease
Lee, Y.-J., Han, S. B., Nam, S.-Y., Oh, K.-W., & Hong, J. T. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1006-7 · Cited by 396
The role of amyloid β peptide 42 in Alzheimer's disease
Findeis, M. A. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.06.006 · Cited by 337
Kanninen, K. M., Heikkinen, R., Malm, T., Rõlova, T., Kemppainen, S., Leinonen, H. M., Ylä‐Herttuala, S., Tanila, H., Levonen, A., Koistinaho, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908397106 · Cited by 296
Wilcock, G. K., Black, S. E., Hendrix, S. B., Zavitz, K. H., Swabb, E. A., & Laughlin, M. A. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70090-5 · Cited by 291
Chen, J.-H., Lin, K.-P., & Chen, Y.-C. (2009) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(09)60402-2 · Cited by 288
Munter, L. M., Voigt, P., Harmeier, A., Kaden, D., Gottschalk, K. E., Weise, C., Pipkorn, R., Schaefer, M. K. E., Langosch, D., & Multhaup, G. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601616 · Cited by 296
Diverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production
Kukar, T. L., Murphy, M. P., Eriksen, J. L., Sagi, S. A., Weggen, S., Smith, T. E., Ladd, T. B., Khan, M. A., Kache, R., Beard, J. D., et al. (2005) · Nature Medicine · doi:10.1038/nm1235 · Cited by 290
Notch post-translationally regulates β-catenin protein in stem and progenitor cells
Kwon, C., Cheng, P. P., King, I. N., Andersen, P., Shenje, L. T., Nigam, V., & Srivastava, D. (2011) · Nature Cell Biology · doi:10.1038/ncb2313 · Cited by 292
Substrate-targeting γ-secretase modulators
Kukar, T. L., Ladd, T. B., Bann, M. A., Fraering, P. C., Narlawar, R., Maharvi, G. M., Healy, B., Chapman, R., Welzel, A. T., Price, R. W., et al. (2008) · Nature · doi:10.1038/nature07055 · Cited by 279
Karran, E. H., & Hardy, J. (2014) · Annals of Neurology · doi:10.1002/ana.24188 · Cited by 279
Slow, E., Graham, R. K., Osmand, A. P., Devon, R. S., Lu, G., Deng, Y. L., Pearson, J., Vaid, K., Bissada, N., Wetzel, R. B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503634102 · Cited by 286
γ-Secretase inhibitors and modulators
Golde, T. E., Koo, E. H., Felsenstein, K. M., Osborne, B. A., & Miele, L. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.06.005 · Cited by 275
Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment
Folch, J., Petrov, D., Ettcheto, M., Abad, S., Sánchez-López, E., García, M. L., Olloquequi, J., Beas-Zarate, C., Auladell, C., & Camins, A. (2016) · Neural Plasticity · doi:10.1155/2016/8501693 · Cited by 270
Axon growth inhibition by RhoA/ROCK in the central nervous system
Fujita, Y., & Yamashita, T. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00338 · Cited by 279
The Life of Pi Star: Exploring the Exciting and Forbidden Worlds of the Benzophenone Photophore
Dormán, G., Nakamura, H., Pulsipher, A., & Prestwich, G. D. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00342 · Cited by 249
Non-canonical Notch signaling: emerging role and mechanism
Andersen, P., Uosaki, H., Shenje, L. T., & Kwon, C. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2012.02.003 · Cited by 238
Jankowsky, J. L., Slunt, H. H., Gonzales, V., Savonenko, A. V., Wen, J. C., Jenkins, N. A., Copeland, N. G., Younkin, L. H., Lester, H. A., Younkin, S. G., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020355 · Cited by 237
Pathogenesis of Alzheimer's disease.
Swerdlow, R. H. (2007) · PubMed Central · Cited by 237
Current and Emerging Drug Treatment Options for Alzheimerʼs Disease
Herrmann, N., Chau, S. A., Kircanski, I., & Lanctôt, K. L. (2011) · Drugs · doi:10.2165/11595870-000000000-00000 · Cited by 245
Inflammatory Aspects of Alzheimer Disease and Other Neurodegenerative Disorders
Schwab, C., & McGeer, P. L. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-13402 · Cited by 235
The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease.
Wilkinson, B. L., & Landreth, G. E. (2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-30 · Cited by 238
Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors
Tayeb, H. O., Yang, H. D., Price, B. H., & Tarazi, F. I. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.12.002 · Cited by 237
Liang, X., Wang, Q., Hand, T. A., Wu, L., BREYER, R. M., Montine, T. J., & Andreasson, K. I. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.3591-05.2005 · Cited by 232
Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions
Cole, G. M., Lim, G. P., Yang, F., Teter, B., Begum, A. N., Ma, Q., Harris‐White, M. E., & Frautschy, S. A. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.005 · Cited by 229
Gasparini, L., Ongini, E., & Wenk, G. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02743.x · Cited by 226
Minocycline affects microglia activation, Aβ deposition, and behavior in APP‐tg mice
Seabrook, T. J., Jiang, L., Maier, M., & Lemere, C. A. (2006) · Glia · doi:10.1002/glia.20338 · Cited by 223
Interleukin-1β impairs brain derived neurotrophic factor-induced signal transduction
Tong, L., Balazs, R., Soiampornkul, R., Thangnipon, W., & Cotman, C. W. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.027 · Cited by 222
Drug discovery in dementia: the role of rodent models
Dam, D. V., & Deyn, P. P. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2075 · Cited by 224
Kotilinek, L., Westerman, M. A., Wang, Q., Panizzon, K. L., Lim, G. P., Simonyi, Á., Lesné, S., Falinska, A. M., Younkin, L. H., Younkin, S. G., et al. (2008) · Brain · doi:10.1093/brain/awn008 · Cited by 223
Neurotherapeutic applications of nanoparticles in Alzheimer’s disease
Sahni, J. K., Doggui, S., Ali, J., Baboota, S., Dao, L., & Ramassamy, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.033 · Cited by 219
Sanz‐Blasco, S., Valero, R. A., Rodríguez‐Crespo, I., Villalobos, C., & Núñez, L. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002718 · Cited by 221
Immunotherapeutic Approaches to Alzheimer's Disease
Monsonego, A., & Weiner, H. L. (2003) · Science · doi:10.1126/science.1088469 · Cited by 217
Mullane, K., & Williams, M. J. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 219
Transgenic models of Alzheimer’s disease: Learning from animals
Spires‐Jones, T. L., & Hyman, B. T. (2005) · NeuroRx · doi:10.1602/neurorx.2.3.423 · Cited by 217
Levites, Y. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25410 · Cited by 209
Inflammation context in Alzheimer’s disease, a relationship intricate to define
Novoa, C., Salazar, P., Cisternas, P., Gherardelli, C., Vera-Salazar, R., Zolezzi, J. M., & Inestrosa, N. C. (2022) · Biological Research · doi:10.1186/s40659-022-00404-3 · Cited by 206
NSAID use and dementia risk in the Cardiovascular Health Study*: Role of APOE and NSAID type
Szekely, C. A., Breitner, J. C. S., Fitzpatrick, A. L., Rea, T. D., Psaty, B. M., Kuller, L. H., & Zandi, P. P. (2008) · Neurology · doi:10.1212/01.wnl.0000284596.95156.48 · Cited by 204
Nonsteroidal anti-inflammatory drugs lower Aβ42 and change presenilin 1 conformation
Lleó, A., Berezovska, O., Herl, L. D., Raju, S., Deng, A., Bacskai, B. J., Frosch, M. P., Irizarry, M. C., & Hyman, B. T. (2004) · Nature Medicine · doi:10.1038/nm1112 · Cited by 198
Immunomodulatory and anti‐inflammatory effects of chondroitin sulphate
du Souich, P., García, A. G., Vergés, J., & Montell, E. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00826.x · Cited by 200
Brain Uptake of Nonsteroidal Anti-Inflammatory Drugs: Ibuprofen, Flurbiprofen, and Indomethacin
Parepally, J. M. R., Mandula, H., & Smith, Q. R. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9905-5 · Cited by 196
Townsend, K. P., & Praticò, D. (2005) · The FASEB Journal · doi:10.1096/fj.04-3620rev · Cited by 194
Imbimbo, B. P., & Giardina, G. A. M. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611795860942 · Cited by 196
Mitani, Y., Yarimizu, J., Saita, K., Uchino, H., Akashiba, H., Shitaka, Y., Ni, K., & Matsuoka, N. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4264-11.2012 · Cited by 203
Recent developments in Alzheimer's disease therapeutics
Rafii, M., & Aisen, P. (2009) · BMC Medicine · doi:10.1186/1741-7015-7-7 · Cited by 204
Nonsteroidal Anti-Inflammatory Drugs Promote Axon Regeneration via RhoA Inhibition
Fu, Q., Hue, J., & Li, S. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4353-06.2007 · Cited by 184
Microglia as a Potential Bridge between the Amyloid β‐Peptide and Tau
Kitazawa, M., Yamasaki, T. R., & LaFerla, F. M. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.006 · Cited by 187
Beher, D., Clarke, E. E., Wrigley, J. D. J., Martin, A. C. L., Nadin, A. J., Churcher, I., & Shearman, M. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404937200 · Cited by 179
The Role of Peroxisome Proliferator-Activated Receptor-γ (PPARγ) in Alzheimer’s Disease
Jiang, Q., Heneka, M. T., & Landreth, G. E. (2008) · CNS Drugs · doi:10.2165/00023210-200822010-00001 · Cited by 176
Yahata, N., Asai, M., Kitaoka, S., Takahashi, K., Asaka, I., Hioki, H., Kaneko, T., Maruyama, K., Saido, T. C., Nakahata, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025788 · Cited by 177
NSAID Exposure and Risk of Alzheimer's Disease: An Updated Meta-Analysis From Cohort Studies
Zhang, C., Wang, Y., Wang, D., Zhang, J., & Zhang, F. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00083 · Cited by 184
Inflammation and NF-κB in Alzheimer's Disease and Diabetes
Granic, I., Dolga, A. M., Nijholt, I. M., van Dijk, G., & Eisel, U. L. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0976 · Cited by 178
Development and Mechanism of γ-Secretase Modulators for Alzheimer’s Disease
Crump, C. J., Johnson, D. S., & Li, Y. (2013) · Biochemistry · doi:10.1021/bi400377p · Cited by 174
Pasqualetti, P., Bonomini, C., Dal Forno, G., Paulon, L., Sinforiani, E., Marra, C., Zanetti, O., & Maria Rossini, P. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03325217 · Cited by 172
5‐Lipoxygenase gene disruption reduces amyloid‐β pathology in a mouse model of Alzheimer's disease
Firuzi, O., Zhuo, J., Chinnici, C. M., Wısnıewskı, T., & Praricò, D. (2007) · The FASEB Journal · doi:10.1096/fj.07-9131.com · Cited by 169
Shibata, N., Motoi, Y., Tomiyama, H., Ohnuma, T., Kuerban, B., Tomson, K., Komatsu, M., Shimazaki, H., Hattori, N., & Arai, H. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000351419 · Cited by 171
Interactions between APP secretases and inflammatory mediators
Sastre, M., Walter, J., & Gentleman, S. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-25 · Cited by 178
γ-secretases: from cell biology to therapeutic strategies
Bergmans, B. A., & Strooper, B. D. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70332-1 · Cited by 179
The Endogenous Estrogen Status Regulates Microglia Reactivity in Animal Models of Neuroinflammation
Vegeto, E., Belcredito, S., Ghisletti, S., Meda, C., Etteri, S., & Maggi, A. C. (2006) · Endocrinology · doi:10.1210/en.2005-1330 · Cited by 178
Peroxisome Proliferator-Activated Receptor γ Induces a Clearance Mechanism for the Amyloid-β Peptide
Espuny-Camacho, I., Serneels, L., Spittaels, K., Merchiers, P., Dominguez, D. I., & Strooper, B. D. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.3987-04.2004 · Cited by 171
Page, R. M., Baumann, K., Tomioka, M., Pérez‐Revuelta, B. I., Fukumori, A., Jacobsen, H., Flohr, A., Luebbers, T., Ozmen, L., Steiner, H., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m708754200 · Cited by 165
γ-Secretase Modulators as Potential Disease Modifying Anti-Alzheimer’s Drugs
Oehlrich, D., Berthelot, D., & Gijsen, H. J. M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101168r · Cited by 163
Chyung, J. H., Raper, D. M. S., & Selkoe, D. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409272200 · Cited by 158
Notch Inhibition as a Promising New Approach to Cancer Therapy
Purow, B. W. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0899-4_23 · Cited by 157
Kim, M., Seong, A., Yoo, J., Jin, C., Lee, Y., Kim, Y. J., Lee, J., Jun, W. J., & Yoon, H. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100262 · Cited by 158
Advancements in nanotherapeutics for Alzheimer’s disease: current perspectives
Harilal, S., Jose, J., Parambi, D. G. T., Kumar, R., Mathew, G. E., Uddin, M. S., Kim, H., & Mathew, B. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13132 · Cited by 158
Dementia Prevention: Methodological Explanations for Inconsistent Results
Coley, N., Andrieu, S., Gardette, V., Guyonnet, S., Sanz, C., Vellas, B. J., & Grand, A. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn010 · Cited by 162
Sung, S., Yang, H., Uryu, K., Lee, E. B., Zhao, L., Shineman, D. W., Trojanowski, J. Q., Lee, V. M. ‐., & Praticò, D. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63269-5 · Cited by 157
Metadata
- Authors
- Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., & Golde, T. E.
- Affiliations
- Mayo Clinic (US)
- University of California San Diego (US)
- Corresponding author
- Golde, Todd E.
- Venue
- Journal of Clinical Investigation
- Published
- 2003-08-01
- Volume
- 112
- Issue
- 3
- Pages
- 440-449
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC166298
- OpenAlex
- W2103071556
- Cited by
- 634
- References
- 52
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 11 · 2023: 11 · 2022: 15 · 2021: 20 · 2020: 14 · 2019: 15 · 2018: 11 · 2017: 18 · 2016: 25 · 2015: 18 · 2014: 31 · 2013: 32 · 2012: 37
- FWCI
- 23.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mayo Foundation for Medical Education and Research
- National Institutes of Health
- National Institute on Aging (P01AG020206, T32AG000216)
- National Institute of Neurological Disorders and Stroke (R01NS039072)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- nonsteroidal anti-inflammatory drugs, gamma-secretase, amyloid-beta 42, Alzheimer's disease, APP transgenic mice, ibuprofen, meclofenamic acid, dapsone, cyclooxygenase inhibition, drug repurposing
- MeSH terms
- Alzheimer Disease, Animals, Anti-Inflammatory Agents, Non-Steroidal, Brain, Cell Line, Female, Flurbiprofen, Humans, Meclofenamic Acid, Mice, Transgenic, Peptide Fragments, Endopeptidases, Protease Inhibitors, Stereoisomerism, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, Mice, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
